Compare · COSM vs PETQ
COSM vs PETQ
Side-by-side comparison of Cosmos Health Inc. (COSM) and PetIQ Inc. (PETQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and PETQ operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- PETQ is the larger of the two at $570.2M, about 16.8x COSM ($33.9M).
- COSM has hit the wire 7 times in the past 4 weeks while PETQ has been quiet.
- PETQ has more recent analyst coverage (8 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- PetIQ Inc.
- Price
- $0.33-3.10%
- $30.99+0.02%
- Market cap
- $33.9M
- $570.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 7
- 0
- Recent ratings
- 0
- 8
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
PetIQ Inc.
PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Latest COSM
- Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
- Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
- SEC Form 8-K filed by Cosmos Health Inc.
- Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
- Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
- Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
- Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
- Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
- Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
- Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
Latest PETQ
- PetIQ Names Camillo Pane as Chief Executive Officer
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- SEC Form 15-12G filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, GENERAL COUNSEL Carter William J. returned 3,497 shares to the company, closing all direct ownership in the company (SEC Form 4)